Zealand dips on Boehringer-paired obesity drug’s Phase III result

Phase 3negativesurvodutidetirzepatideNegative

AI Analysis

Summary

Zealand's survodutide failed to show superior weight loss efficacy compared to Eli Lilly's tirzepatide in a Phase III trial for obesity with type 2 diabetes. The negative result prompted a market decline for Zealand shares.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

survodutide did not demonstrate greater weight loss compared to tirzepatide in obesity with type 2 diabetes

Importance:7/10

Sentiment:

-0.70

obesitytype 2 diabetesPhase 3weight losscompetitive comparison

Related Companies

$ZEAL

Read the original article

Published by Clinical Trials Arena on October 1, 2026 3:10 PM

Read Original